Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Estimating the early death toll of COVID-19 in the United States

Daniel M. Weinberger, Ted Cohen, Forrest W. Crawford, Farzad Mostashari, Don Olson, Virginia E Pitzer, Nicholas G Reich, Marcus Russi, Lone Simonsen, Anne Watkins, Cecile Viboud
doi: https://doi.org/10.1101/2020.04.15.20066431
Daniel M. Weinberger
1Department of Epidemiology of Microbial Diseases and the Public Health Modeling Unit, Yale School of Public Health, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: daniel.weinberger@yale.edu
Ted Cohen
1Department of Epidemiology of Microbial Diseases and the Public Health Modeling Unit, Yale School of Public Health, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Forrest W. Crawford
2Department of Biostatistics and the Public Health Modeling Unit, Yale School of Public Health, New Haven, CT; Yale Departments of Ecology and Evolutionary Biology, Statistics & Data Science, Yale School of Management
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Farzad Mostashari
3Aledade, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Don Olson
4Department of Health and Mental Hygiene, New York City, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Virginia E Pitzer
1Department of Epidemiology of Microbial Diseases and the Public Health Modeling Unit, Yale School of Public Health, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas G Reich
5Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts, Amherst, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcus Russi
1Department of Epidemiology of Microbial Diseases and the Public Health Modeling Unit, Yale School of Public Health, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lone Simonsen
6Department of Science and Environment, Roskilde University, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Watkins
1Department of Epidemiology of Microbial Diseases and the Public Health Modeling Unit, Yale School of Public Health, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cecile Viboud
7Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Efforts to track the severity and public health impact of the novel coronavirus, COVID-19, in the US have been hampered by testing issues, reporting lags, and inconsistency between states.

Evaluating unexplained increases in deaths attributed to broad outcomes, such as pneumonia and influenza (P&I) or all causes, can provide a more complete and consistent picture of the burden caused by COVID-19.

Methods We evaluated increases in the occurrence of deaths due to P&I above a seasonal baseline (adjusted for influenza activity) or due to any cause across the United States in February and March 2020. These estimates are compared with reported deaths due to COVID-19 and with testing data.

Results There were notable increases in the rate of death due to P&I in February and March 2020. In a number of states, these deaths pre-dated increases in COVID-19 testing rates and were not counted in official records as related to COVID-19. There was substantial variability between states in the discrepancy between reported rates of death due to COVID-19 and the estimated burden of excess deaths due to P&I. The increase in all-cause deaths in New York and New Jersey is 1.5-3 times higher than the official tally of COVID-19 confirmed deaths or the estimated excess death due to P&I.

Conclusions Excess P&I deaths provide a conservative estimate of COVID-19 burden and indicate that COVID-19-related deaths are missed in locations with inadequate testing or intense pandemic activity.

Evidence before this study Deaths due to the novel coronavirus, COVID-19, have been increasing sharply in the United States since mid-March. However, efforts to track the severity and public health impact of COIVD-19 in the US have been hampered by testing issues, reporting lags, and inconsistency between states. As a result, the reported number of deaths likely represents an underestimate of the true burden.

Added Value of this study We evaluate increases in deaths due to pneumonia across the United States and relate these increases to the number of reported deaths due to COVID-19 in different states and evaluate the trajectories of these increases in relation to the volume of testing and to indicators of COVID-19 morbidity. This provides a more complete picture of mortality due to COVID-19 in the US and demonstrates how delays in testing led to many coronavirus deaths not being counted in certain states.

Implications of all the available evidence The number of deaths reported to be due to COVID-19 represents just a fraction of the deaths linked to the pandemic. Monitoring trends in deaths due to pneumonia and all-causes provides a more complete picture of the tool of the disease.

Competing Interest Statement

DMW has received consulting fees from Pfizer, Merck, GSK, and Affinivax for topics unrelated to this manuscript and is Principal Investigator on a research grant from Pfizer on an unrelated topic. VEP has received reimbursement from Merck and Pfizer for travel expenses to Scientific Input Engagements unrelated to the topic of this manuscript. All other authors report no relevant conflicts.

Funding Statement

DMW acknowledges support from grants R01AI123208 and R01AI137093 from the National Institute of Allergy and Infectious Diseases/National Institutes of Health. VEP acknowledges support from grants R01AI112970 and R01AI137093 from the National Institute of Allergy and Infectious Diseases/National Institutes of Health. NGR acknowledges support from grant R35GM119582 from the National Institute of General Medical Sciences/National Institutes of Health and 1U01IP001122 from the Centers for Disease Control and Prevention (CDC). TC acknowledges support from R01AI146555 from the National Institute of Allergy and Infectious Diseases/National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, New York City Department of Health and Mental Hygiene or CDC. LS acknowledges support from the Carlsberg Foundation grant # CF20-0046. FWC acknowledges support from NICHD grant 1DP2HD091799-01.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* Daniel Weinberger, PO Box 208034, New Haven, CT 06520, daniel.weinberger{at}yale.edu. 203-737-6004

  • DISCLAIMER: This study does not necessarily represent the views of the NIH or the US government.

  • FUNDING: DMW acknowledges support from grants R01AI123208 and R01AI137093 from the National Institute of Allergy and Infectious Diseases/National Institutes of Health. VEP acknowledges support from grants R01AI112970 and R01AI137093 from the National Institute of Allergy and Infectious Diseases/National Institutes of Health. NGR acknowledges support from grant R35GM119582 from the National Institute of General Medical Sciences/National Institutes of Health and 1U01IP001122 from the Centers for Disease Control and Prevention (CDC). TC acknowledges support from R01AI146555 from the National Institute of Allergy and Infectious Diseases/National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, New York City Department of Health and Mental Hygiene or CDC. LS acknowledges support from the Carlsberg Foundation grant # CF20-0046. FWC acknowledges support from NICHD grant 1DP2HD091799-01.

  • CONFLICTS OF INTEREST: DMW has received consulting fees from Pfizer, Merck, GSK, and Affinivax for topics unrelated to this manuscript and is Principal Investigator on a research grant from Pfizer on an unrelated topic. VEP has received reimbursement from Merck and Pfizer for travel expenses to Scientific Input Engagements unrelated to the topic of this manuscript. All other authors report no relevant conflicts.

Data Availability

All analysis scripts and archives of the data are available from https://github.com/weinbergerlab/excess_pi_covid

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted April 29, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Estimating the early death toll of COVID-19 in the United States
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Estimating the early death toll of COVID-19 in the United States
Daniel M. Weinberger, Ted Cohen, Forrest W. Crawford, Farzad Mostashari, Don Olson, Virginia E Pitzer, Nicholas G Reich, Marcus Russi, Lone Simonsen, Anne Watkins, Cecile Viboud
medRxiv 2020.04.15.20066431; doi: https://doi.org/10.1101/2020.04.15.20066431
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Estimating the early death toll of COVID-19 in the United States
Daniel M. Weinberger, Ted Cohen, Forrest W. Crawford, Farzad Mostashari, Don Olson, Virginia E Pitzer, Nicholas G Reich, Marcus Russi, Lone Simonsen, Anne Watkins, Cecile Viboud
medRxiv 2020.04.15.20066431; doi: https://doi.org/10.1101/2020.04.15.20066431

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (194)
  • Anesthesia (54)
  • Cardiovascular Medicine (488)
  • Dentistry and Oral Medicine (89)
  • Dermatology (56)
  • Emergency Medicine (168)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (211)
  • Epidemiology (5658)
  • Forensic Medicine (3)
  • Gastroenterology (215)
  • Genetic and Genomic Medicine (856)
  • Geriatric Medicine (88)
  • Health Economics (229)
  • Health Informatics (759)
  • Health Policy (388)
  • Health Systems and Quality Improvement (250)
  • Hematology (105)
  • HIV/AIDS (181)
  • Infectious Diseases (except HIV/AIDS) (6453)
  • Intensive Care and Critical Care Medicine (388)
  • Medical Education (116)
  • Medical Ethics (28)
  • Nephrology (90)
  • Neurology (845)
  • Nursing (44)
  • Nutrition (141)
  • Obstetrics and Gynecology (161)
  • Occupational and Environmental Health (258)
  • Oncology (514)
  • Ophthalmology (162)
  • Orthopedics (44)
  • Otolaryngology (105)
  • Pain Medicine (45)
  • Palliative Medicine (21)
  • Pathology (149)
  • Pediatrics (248)
  • Pharmacology and Therapeutics (146)
  • Primary Care Research (112)
  • Psychiatry and Clinical Psychology (958)
  • Public and Global Health (2219)
  • Radiology and Imaging (375)
  • Rehabilitation Medicine and Physical Therapy (172)
  • Respiratory Medicine (310)
  • Rheumatology (109)
  • Sexual and Reproductive Health (80)
  • Sports Medicine (82)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)